Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: ge who wrote (7840)	4/8/2000 12:23:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

CYTO has a lot more going for it today than it did one year ago. I most obvious is the exposure, for good or bad, of biotech issues to the "general" public. CYTO has three APPROVED drugs for sale. ProstaScintÆ was just named a "first line" evaluation mechanism for detecting the extent of Prostrate cancer. It has suffered from a myriad of problems over the last 3-4 yr time frame including: mismanagement, too many cash hunger ventures, terrible marketing partners, revolving door CEO?s. All these combined to force death spiral, fire sale, floorless convertible issues that knocked a promising company into the never-never world on the verge of bankruptcy. Shorts made a ton of money once that issue came to light. CYTO was scraping from Q to Q for any CASH! All they could do was print more shares and hope for a buyer. The search for a CEO turned up what I consider a gem so far. Dr. Reiser has slashed SPENDING, sold assets and turned this ship on the right course. The marketing aspect is still a work in progress. I personally believe that CYTO will turn profitable once this arm is in place. PSMA looks interesting and CYTO has some patents in this area. Elan licensing should also bring in some $ The Axcell Division has what looks like some very promising technology that may or may not get to market on time or be price competitive with what others have. InfoMax seems like a solid partner to help bring this KEY technology forward. Remember, slice and dice the amino acids up to discover the "code", but functionality lies at the protein level. Today, IMHO, it is undervalued compared to some of its competition (Curagen). Jim